Tazorac
Loading...Tazorac Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Pregnancy Category X. See CONTRAINDICATIONS section. Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC® Gel is used. The possibility that a woman of childbearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mIU/mL for hCG should be obtained within 2 weeks prior to TAZORAC® Gel therapy, which should begin during a normal menstrual period.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
TAZORAC® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement.
TAZORAC® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.
The efficacy of TAZORAC® Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established.
History
There is currently no drug history available for this drug.
Other Information
TAZORAC® Gel is a translucent, aqueous gel and contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical dermatologic use only. The active ingredient is represented by the following structural formula:
Chemical Name:
Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl) ethynyl] nicotinate
Contains:
Active: Tazarotene................................... 0.05% or 0.1% (w/w)Preservative: Benzyl alcohol.................................. 1.0% (w/w)
Inactives: Ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, carbomer 934P, edetate disodium, hexylene glycol, poloxamer 407, polyethylene glycol 400, polysorbate 40, purified water, and tromethamine.
Sources
Tazorac Manufacturers
-
Physicians Total Care, Inc.
![Tazorac (Tazarotene) Gel [Physicians Total Care, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Tazorac | Physicians Total Care, Inc.
General:Application may cause excessive irritation in the skin of certain sensitive individuals. In cases where it has been necessary to temporarily discontinue therapy, or the dosing has been reduced to a lower concentration (in patients with psoriasis) or to an interval the patient can tolerate, therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate the treatment. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Efficacy has not been established for less than once daily dosing frequencies.
For psoriasis: It is recommended that treatment start with TAZORAC® 0.05% Gel, with strength increased to 0.1% if tolerated and medically indicated. Apply TAZORAC® Gel once a day, in the evening, to psoriatic lesions, using enough (2 mg/cm2) to cover only the lesion with a thin film to no more than 20% of body surface area. If a bath or shower is taken prior to application, the skin should be dry before applying the gel. If emollients are used, they should be applied at least an hour before application of TAZORAC® Gel. Because unaffected skin may be more susceptible to irritation, application of tazarotene to these areas should be carefully avoided. TAZORAC® Gel was investigated for up to 12 months during clinical trials for psoriasis.
For acne: Cleanse the face gently. After the skin is dry, apply a thin film of TAZORAC® Gel 0.1% (2 mg/cm2) once a day, in the evening, to the skin where acne lesions appear. Use enough to cover the entire affected area. TAZORAC® Gel was investigated for up to 12 weeks during clinical trials for acne.
-
Allergan, Inc.
Tazorac |
2.1 PsoriasisIt is recommended that treatment starts with TAZORAC® Cream, 0.05%, with strength increased to 0.1% if tolerated and medically indicated. Apply a thin film (2 mg/cm2) of TAZORAC® Cream once per day, in the evening, to cover only the psoriatic lesions. If a bath or shower is taken prior to application, the skin should be dry before applying the cream. If emollients are used, they should be applied at least an hour before application of TAZORAC® Cream. Because unaffected skin may be more susceptible to irritation, application of TAZORAC® Cream to these areas should be carefully avoided.
2.2 AcneCleanse the face gently. After the skin is dry, apply a thin layer (2 mg/cm2) of TAZORAC® Cream 0.1% once per day, in the evening, to the skin areas where acne lesions appear. Use enough to cover the entire affected area.
TAZORAC® Cream is for topical use only. TAZORAC® Cream is not for ophthalmic, oral, or intravaginal use. If contact with eyes occurs, rinse thoroughly with water.
-
Allergan, Inc.
Tazorac | Allergan, Inc.
General: Application may cause excessive irritation in the skin of certain sensitive individuals. In cases where it has been necessary to temporarily discontinue therapy, or the dosing has been reduced to a lower concentration (in patients with psoriasis) or to an interval the patient can tolerate, therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate the treatment. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Efficacy has not been established for less than once daily dosing frequencies.
For Psoriasis: It is recommended that treatment start with TAZORAC® 0.05% Gel, with strength increased to 0.1% if tolerated and medically indicated. Apply TAZORAC® Gel once a day, in the evening, to psoriatic lesions, using enough (2 mg/cm2) to cover only the lesion with a thin film to no more than 20% of body surface area. If a bath or shower is taken prior to application, the skin should be dry before applying the gel. If emollients are used, they should be applied at least an hour before application of TAZORAC® Gel. Because unaffected skin may be more susceptible to irritation, application of tazarotene to these areas should be carefully avoided. TAZORAC® Gel was investigated for up to 12 months during clinical trials for psoriasis.
For Acne: Cleanse the face gently. After the skin is dry, apply a thin film of TAZORAC® Gel 0.1% (2 mg/cm2) once a day, in the evening, to the skin where acne lesions appear. Use enough to cover the entire affected area. TAZORAC® Gel was investigated for up to 12 weeks during clinical trials for acne.
![Tazorac (Tazarotene) Cream [Allergan, Inc.
]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd02ea43-7668-4872-a655-ee31c456e345&name=carton1.jpg)
![Tazorac (Tazarotene) Gel [Allergan, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&name=carton1.jpg)
Login To Your Free Account